Oral nanozyme-engineered probiotics for the treatment of ulcerative colitis. Issue 21 (3rd May 2022)

• Record Type: Journal Article
• Authors: Zhao, Huan; Du, Yurong; Liu, Lei; Du, Yabing; Cui, Kang; Yu, Pu; Li, Li; Zhu, Yanjie; Jiang, Wei; Li, Zhen; Tang, Hao; Ma, Wang
• Is Part Of: Journal of materials chemistry. Volume 10:Issue 21(2022)
• Page Start: 4002
• Page End: 4011
• Publication Date: 2022-05-03
• Subjects: Materials -- Periodicals; Chemistry, Analytic -- Periodicals; Biomedical materials -- Research -- Periodicals; 543.0284
• DOI: 10.1039/d2tb00300g
• Languages: English
• ISSNs: 2050-750X

Abstract

Abstract : Pt-lipid coated probiotics have better resistance to the harsh environment of the gastrointestinal tract, improving the homeostasis of the intestinal epithelial barrier and offering considerable potential for the treatment of ulcerative colitis. Abstract : Probiotic-based therapy for ulcerative colitis (UC) is a novel and promising approach that has gained much popularity in recent years. However, probiotics may be easily captured and destroyed by the harsh in vivo environment, which limits their application prospects to a large extent. This work introduces a versatile facile approach for decorating individual probiotics with nanozyme coatings, named Pt-Lipid@EcN. A bimolecular lipid coating is deposited on the surface of probiotics used in the oral treatment of UC using simple self-assembly with a liposome under cytocompatible conditions, and it acts as armor to effectively protect the probiotics from strong digestive acids and enzymes. The obtained results indicated that the liposome-coated Escherichia coli Nissle (EcN) 1917 could significantly improve the colonization rate of the microorganisms in the intestinal tract. We also explored the specific mechanism of Pt-Lipid@EcN to improve the behavior of murine UC models, including reduction of inflammatory effects and histological injury, and regulation of epithelial barrier homeostasis in the intestine. The nanozyme-shielded probiotic exhibited enhanced anti-inflammatory ability in vivo, introducing novel strategies for the application of nanozyme biomedicine in the treatment of colonic inflammatory diseases.